Cargando…

Novel method to select meaningful outcomes for evaluation in clinical trials

BACKGROUND: A standardised framework for selecting outcomes for evaluation in trials has been proposed by the Core Outcome Measures in Effectiveness Trials working group. However, this method does not specify how to ensure that the outcomes that are selected are causally related to the disease and t...

Descripción completa

Detalles Bibliográficos
Autores principales: McLeod, Charlie, Norman, Richard, Wood, Jamie, Mulrennan, Siobhain, Morey, Sue, Schultz, André, Messer, Mitch, Spaapen, Kate, Stoneham, Matthew, Wu, Yue, Smyth, Alan, Blyth, Christopher, Webb, Steve, Mascaro, Steven, Woodberry, Owen, Snelling, Tom
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8499339/
https://www.ncbi.nlm.nih.gov/pubmed/34620699
http://dx.doi.org/10.1136/bmjresp-2021-000877
_version_ 1784580304583786496
author McLeod, Charlie
Norman, Richard
Wood, Jamie
Mulrennan, Siobhain
Morey, Sue
Schultz, André
Messer, Mitch
Spaapen, Kate
Stoneham, Matthew
Wu, Yue
Smyth, Alan
Blyth, Christopher
Webb, Steve
Mascaro, Steven
Woodberry, Owen
Snelling, Tom
author_facet McLeod, Charlie
Norman, Richard
Wood, Jamie
Mulrennan, Siobhain
Morey, Sue
Schultz, André
Messer, Mitch
Spaapen, Kate
Stoneham, Matthew
Wu, Yue
Smyth, Alan
Blyth, Christopher
Webb, Steve
Mascaro, Steven
Woodberry, Owen
Snelling, Tom
author_sort McLeod, Charlie
collection PubMed
description BACKGROUND: A standardised framework for selecting outcomes for evaluation in trials has been proposed by the Core Outcome Measures in Effectiveness Trials working group. However, this method does not specify how to ensure that the outcomes that are selected are causally related to the disease and the health intervention being studied. Causal network diagrams may help researchers identify outcomes that are both clinically meaningful and likely to be causally dependent on the intervention, and endpoints that are, in turn, causally dependent on those outcomes. We aimed to (1) develop a generalisable method for selecting outcomes and endpoints in trials and (2) apply this method to select outcomes for evaluation in a trial investigating treatment strategies for pulmonary exacerbations of cystic fibrosis (CF). METHODS: We conducted a series of online surveys and workshops among people affected by CF. We used a modified Delphi approach to develop a consensus list of important outcomes. A workshop involving domain experts elicited how these outcomes were causally related to the underlying pathophysiological processes. Meaningful outcomes were prioritised based on the extent to which each outcome captured separate rather than common aspects of the underlying pathophysiological process. RESULTS: The 10 prioritised outcomes were: breathing difficulty/pain, sputum production/clearance, fatigue, appetite, pain (not related to breathing), motivation/demoralisation, fevers/night sweats, treatment burden, inability to meet personal goals and avoidance of gastrointestinal symptoms. CONCLUSIONS: This proposed method for selecting meaningful outcomes for evaluation in clinical trials may improve the value of research as a basis for clinical decisions.
format Online
Article
Text
id pubmed-8499339
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-84993392021-10-22 Novel method to select meaningful outcomes for evaluation in clinical trials McLeod, Charlie Norman, Richard Wood, Jamie Mulrennan, Siobhain Morey, Sue Schultz, André Messer, Mitch Spaapen, Kate Stoneham, Matthew Wu, Yue Smyth, Alan Blyth, Christopher Webb, Steve Mascaro, Steven Woodberry, Owen Snelling, Tom BMJ Open Respir Res Cystic Fibrosis BACKGROUND: A standardised framework for selecting outcomes for evaluation in trials has been proposed by the Core Outcome Measures in Effectiveness Trials working group. However, this method does not specify how to ensure that the outcomes that are selected are causally related to the disease and the health intervention being studied. Causal network diagrams may help researchers identify outcomes that are both clinically meaningful and likely to be causally dependent on the intervention, and endpoints that are, in turn, causally dependent on those outcomes. We aimed to (1) develop a generalisable method for selecting outcomes and endpoints in trials and (2) apply this method to select outcomes for evaluation in a trial investigating treatment strategies for pulmonary exacerbations of cystic fibrosis (CF). METHODS: We conducted a series of online surveys and workshops among people affected by CF. We used a modified Delphi approach to develop a consensus list of important outcomes. A workshop involving domain experts elicited how these outcomes were causally related to the underlying pathophysiological processes. Meaningful outcomes were prioritised based on the extent to which each outcome captured separate rather than common aspects of the underlying pathophysiological process. RESULTS: The 10 prioritised outcomes were: breathing difficulty/pain, sputum production/clearance, fatigue, appetite, pain (not related to breathing), motivation/demoralisation, fevers/night sweats, treatment burden, inability to meet personal goals and avoidance of gastrointestinal symptoms. CONCLUSIONS: This proposed method for selecting meaningful outcomes for evaluation in clinical trials may improve the value of research as a basis for clinical decisions. BMJ Publishing Group 2021-10-07 /pmc/articles/PMC8499339/ /pubmed/34620699 http://dx.doi.org/10.1136/bmjresp-2021-000877 Text en © Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Cystic Fibrosis
McLeod, Charlie
Norman, Richard
Wood, Jamie
Mulrennan, Siobhain
Morey, Sue
Schultz, André
Messer, Mitch
Spaapen, Kate
Stoneham, Matthew
Wu, Yue
Smyth, Alan
Blyth, Christopher
Webb, Steve
Mascaro, Steven
Woodberry, Owen
Snelling, Tom
Novel method to select meaningful outcomes for evaluation in clinical trials
title Novel method to select meaningful outcomes for evaluation in clinical trials
title_full Novel method to select meaningful outcomes for evaluation in clinical trials
title_fullStr Novel method to select meaningful outcomes for evaluation in clinical trials
title_full_unstemmed Novel method to select meaningful outcomes for evaluation in clinical trials
title_short Novel method to select meaningful outcomes for evaluation in clinical trials
title_sort novel method to select meaningful outcomes for evaluation in clinical trials
topic Cystic Fibrosis
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8499339/
https://www.ncbi.nlm.nih.gov/pubmed/34620699
http://dx.doi.org/10.1136/bmjresp-2021-000877
work_keys_str_mv AT mcleodcharlie novelmethodtoselectmeaningfuloutcomesforevaluationinclinicaltrials
AT normanrichard novelmethodtoselectmeaningfuloutcomesforevaluationinclinicaltrials
AT woodjamie novelmethodtoselectmeaningfuloutcomesforevaluationinclinicaltrials
AT mulrennansiobhain novelmethodtoselectmeaningfuloutcomesforevaluationinclinicaltrials
AT moreysue novelmethodtoselectmeaningfuloutcomesforevaluationinclinicaltrials
AT schultzandre novelmethodtoselectmeaningfuloutcomesforevaluationinclinicaltrials
AT messermitch novelmethodtoselectmeaningfuloutcomesforevaluationinclinicaltrials
AT spaapenkate novelmethodtoselectmeaningfuloutcomesforevaluationinclinicaltrials
AT stonehammatthew novelmethodtoselectmeaningfuloutcomesforevaluationinclinicaltrials
AT wuyue novelmethodtoselectmeaningfuloutcomesforevaluationinclinicaltrials
AT smythalan novelmethodtoselectmeaningfuloutcomesforevaluationinclinicaltrials
AT blythchristopher novelmethodtoselectmeaningfuloutcomesforevaluationinclinicaltrials
AT webbsteve novelmethodtoselectmeaningfuloutcomesforevaluationinclinicaltrials
AT mascarosteven novelmethodtoselectmeaningfuloutcomesforevaluationinclinicaltrials
AT woodberryowen novelmethodtoselectmeaningfuloutcomesforevaluationinclinicaltrials
AT snellingtom novelmethodtoselectmeaningfuloutcomesforevaluationinclinicaltrials